Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations
(2007) In Medical Oncology 24(3). p.267-272- Abstract
- Due to concerns related to treatment with erythropoietin (EPO) and possible negative effects on tumour control, a workshop was organised by the Medical Products Agency of Sweden with the aim to revise national treatment guidelines if needed. In patients with solid tumours, conflicting results have been reported with respect to tumour control and survival. Until further notice it is therefore recommended that EPO should be used restrictively in the treatment of patients with cancer and that the anticipated improvement in quality of life should be evaluated against potential risks.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/657078
- author
- Ahlqvist-Rastad, Jane ; Albertsson, Maria ; Bergh, Jonas ; Birgegard, Gunnar ; Johansson, Peter ; Jonsson, Bertil ; Kjellén, Elisabeth LU ; Pahlman, Sven ; Zackrisson, Bjorn and Osterborg, Anders
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- erythropoietin, safety, cancer therapy, epoetin, anemia, receptor
- in
- Medical Oncology
- volume
- 24
- issue
- 3
- pages
- 267 - 272
- publisher
- Humana Press
- external identifiers
-
- wos:000249339900001
- scopus:36248997063
- ISSN
- 1559-131X
- DOI
- 10.1007/s12032-007-0037-5
- language
- English
- LU publication?
- yes
- id
- 1f09295c-bded-48ca-9f6c-9d9bbbeaa107 (old id 657078)
- alternative location
- http://humanapress.com/index.php?option=com_journalshome&task=articledetails&category=journals&article_code=MO:24:3:267
- date added to LUP
- 2016-04-01 16:31:23
- date last changed
- 2022-01-28 20:17:46
@article{1f09295c-bded-48ca-9f6c-9d9bbbeaa107, abstract = {{Due to concerns related to treatment with erythropoietin (EPO) and possible negative effects on tumour control, a workshop was organised by the Medical Products Agency of Sweden with the aim to revise national treatment guidelines if needed. In patients with solid tumours, conflicting results have been reported with respect to tumour control and survival. Until further notice it is therefore recommended that EPO should be used restrictively in the treatment of patients with cancer and that the anticipated improvement in quality of life should be evaluated against potential risks.}}, author = {{Ahlqvist-Rastad, Jane and Albertsson, Maria and Bergh, Jonas and Birgegard, Gunnar and Johansson, Peter and Jonsson, Bertil and Kjellén, Elisabeth and Pahlman, Sven and Zackrisson, Bjorn and Osterborg, Anders}}, issn = {{1559-131X}}, keywords = {{erythropoietin; safety; cancer therapy; epoetin; anemia; receptor}}, language = {{eng}}, number = {{3}}, pages = {{267--272}}, publisher = {{Humana Press}}, series = {{Medical Oncology}}, title = {{Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations}}, url = {{http://dx.doi.org/10.1007/s12032-007-0037-5}}, doi = {{10.1007/s12032-007-0037-5}}, volume = {{24}}, year = {{2007}}, }